Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna (MRNA) remains at the forefront of mRNA technology innovation, developing transformative therapies for infectious diseases, oncology, and rare conditions. This dedicated news hub provides investors and healthcare professionals with essential updates directly from the company and verified sources.
Access official press releases covering clinical trial results, regulatory milestones, and strategic partnerships, alongside analysis of quarterly earnings and pipeline developments. Our curated collection ensures you stay informed about Moderna's progress in advancing mRNA-based medicines without promotional bias.
Key updates include developments in respiratory vaccines, cancer immunotherapy candidates, and rare disease treatments. Bookmark this page for real-time access to Moderna's verified announcements and objective reporting on one of biotechnology's most innovative platforms.
Moderna has appointed Arpa Garay as the new Chief Commercial Officer, effective May 31, 2022. Ms. Garay brings over 16 years of experience from Merck & Co., where she was Chief Marketing Officer and led significant global marketing strategies. Her extensive background in oncology and digital marketing is expected to bolster Moderna's commercial efforts in mRNA therapeutics. Moderna emphasizes its commitment to innovative therapies, aiming to leverage Ms. Garay's expertise to enhance patient outcomes worldwide.
Moderna's bivalent booster candidate mRNA-1273.211 shows enhanced neutralizing titers against COVID-19 variants, including Omicron. This candidate demonstrated superiority for six months after administration against variants of concern. The tolerability and safety were consistent with the authorized mRNA-1273 booster. Additionally, Moderna is assessing another bivalent booster, mRNA-1273.214, in a Phase 2/3 study, with data expected in Q2 2022. These findings support Moderna's strategy to address ongoing virus mutations and enhance vaccine effectiveness.
Moderna (NASDAQ:MRNA) will host a live conference call on May 4, 2022, at 8:00 a.m. ET to discuss its Q1 2022 financial results and provide a corporate update. Investors can join the call by dialing 866-922-5185 (domestic) or 409-937-8950 (international) with conference ID 2083116. Additionally, a webcast will be available under the Investors section of Moderna's website. Over its decade of existence, Moderna has developed a diverse portfolio of mRNA-based therapeutics and vaccines, including significant contributions to the COVID-19 pandemic response.
Moderna announces the appointment of Jorge Gomez as Chief Financial Officer, effective May 9, 2022. He joins from Dentsply Sirona, where he led the global finance organization. Gomez's experience in multinational healthcare companies and his focus on sustainability aligns with Moderna's vision. The current CFO, David Meline, will retire but assist in the transition. Moderna has evolved into a global commercial entity specializing in mRNA therapeutics and vaccines, following significant advancements in science, technology, and manufacturing.
Moderna (NASDAQ:MRNA) announced the initiation of a Phase 1/2 clinical trial for its seasonal influenza vaccine candidates, mRNA-1020 and mRNA-1030. The study will assess the safety, reactogenicity, and immunogenicity of these vaccines targeting hemagglutinin and neuraminidase antigens. Approximately 560 participants will be enrolled, and the trial aims to produce a vaccine with broader immunity against strains recommended by the WHO, including influenza A and B viruses. Moderna's mRNA platform aims to facilitate rapid vaccine matching with circulating strains.
Moderna and IAVI have announced a collaboration to utilize mRNA technology to address critical global health issues, including HIV, tuberculosis, antimicrobial-resistant pathogens, and COVID-19.
This partnership aims to develop vaccines and antibodies, particularly targeting low-income regions. A notable project is the Phase I clinical trial of an HIV vaccine (IAVI G002), with further trials planned in South Africa and Rwanda.
The collaboration seeks to leverage the rapid production capabilities of mRNA to solve urgent public health challenges.
Moderna has received FDA approval for a second booster dose of its COVID-19 vaccine, mRNA-1273, at a 50 µg dose for adults aged 50+ and immunocompromised individuals over 18. This amendment to the emergency use authorization (EUA) will enable millions to enhance their immunity as the virus evolves, particularly against the BA.2 variant. The decision is supported by data from Israel highlighting the vaccine's safety and efficacy during the Omicron surge. Moderna continues to monitor real-world data and conduct clinical trials for Omicron-specific boosters.
Moderna (MRNA) has reported significant advancements in its mRNA pipeline, including successful results from a Phase 2/3 study of its COVID-19 vaccine for children aged 6 months to under 6 years, prompting regulatory submissions. The company is also seeking FDA emergency use authorization for children aged 6 to under 12. Additionally, interim data from a Phase 2 study of its influenza vaccine candidate, mRNA-1010, shows promising immunogenicity. Moderna increased its signed purchase agreements for 2022 to $21 billion, reflecting robust demand for its vaccine products.
Moderna, Inc. (NASDAQ:MRNA) has finalized a strategic partnership with the Australian Federal Government to establish a state-of-the-art mRNA vaccine manufacturing facility in Melbourne. This facility aims to produce up to 100 million vaccine doses annually, targeting respiratory viruses including COVID-19. Construction is set to begin by late 2022 and aims for operational status by 2024. The partnership also includes job creation and support for Australia’s mRNA research ecosystem.
FAQ
What is the current stock price of Moderna (MRNA)?
What is the market cap of Moderna (MRNA)?
